https://www.selleckchem.com/pr....oducts/abraxane-nab-
1 ± 9mmHg to 17.3 ± 8mmHg (p = 0.041) and right atrial pressure from 10.3 ± 6mmHg to 8.0 ± 6mmHg (p = 0.013) from baseline to 5months. In addition, propensity score matching showed that PASCAL and MitraClip procedures resulted in equally hemodynamic and functional improvement. MR reduction of severe MR with the PASCAL device is feasible and safe regardless of etiologies. Mid-term follow-up at 5months showed a sustained MR reduction, improvement of exercise capacity, quality of life, proBNP levels and hemodynamics regardi
Like
Comment
Share
